OpenNashEarnings

Illumina (ILMN) · Life Sciences

Illumina Q2 FY2026 earnings: summary, key numbers & outlook

Results filed 30 Jul 2026 · Quarter ended 28 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Illumina's NovaSeq X demand stayed high with more than 95 placements, while clinical customers expanded sequencing use and the company added spatial and multiomics offerings.

Clinical customers drove the quarter, as Illumina says its technology is letting them expand sequencing-intensive applications. NovaSeq X demand stayed high more than three years after launch, with more than 95 placements. Clinical markets make up approximately 65% of sequencing consumables revenue. This summer Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, and biopharma interest is growing with over 300 million cells delivered to date.

Management is steering Illumina toward a broader multiomics ecosystem built on NovaSeq X, with a strategy of delivering the highest quality insights at the lowest end-to-end cost. The tension is execution and cost. Integrating the SomaLogic business and managing proteomics partners is a stated risk, supply investments carry real costs that Illumina is partly sharing with customers, and its place on China's Unreliable Entities List and U.S. tariffs add uncertainty.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Key numbers

Revenue · GAAP
$1.16 billion

up 9.5% from Q2 2025

Net income · GAAP
$207.0M

from $235 in Q2 2025

Diluted EPS · GAAP
$1.35

from $1.49 in Q2 2025

Diluted EPS · non-GAAP
$1.31

from $1.19 in Q2 2025

Gross margin · GAAP
66.4%

from 65.6% in Q2 2025

Gross margin · non-GAAP
68.2%

from 69.4% in Q2 2025

Operating income · GAAP
$245.0M

from $214 in Q2 2025

Operating margin · GAAP
21.1%

from 20.2% in Q2 2025

Segment or metricValueChange
Product revenue$982.0Mfrom $912 in Q2 2025
Service and other revenue177.0Mfrom 147 in Q2 2025
ROW organic revenue growth8.1%excludes currency, acquisitions and China
Where each number comes from
  • Revenue: “Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China”
  • Net income: “Income before income taxes | 260 | 306 | 417 | 488 Provision for income taxes | 53 | 71 | 77 | 122 Net income | $207 | $235 | $340 | $366”
  • Diluted EPS: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
  • Diluted EPS: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
  • Gross margin: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
  • Gross margin: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
  • Operating income: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
  • Operating margin: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
  • Product revenue: “Revenue: Product revenue | $982 | $912 | $1,899 | $1,793 Service and other revenue | 177 | 147 | 352 | 307 Total revenue | 1,159 | 1,059”
  • Service and other revenue: “Revenue: Product revenue | $982 | $912 | $1,899 | $1,793 Service and other revenue | 177 | 147 | 352 | 307 Total revenue | 1,159 | 1,059”
  • ROW organic revenue growth: “Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 FY2026vs year agovs last quarter
Revenue$1.2B+9.4%+6.2%
Operating income$245.0M+14.5%+17.2%
Net income$207.0M−11.9%+54.5%
Diluted EPS$1.35−9.4%+55.2%
Free cash flow$161.0M−21.1%−35.9%
Gross margin66.4%+0.8 pts+0.3 pts
Operating margin21.1%+0.9 pts+1.9 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Total revenuefiscal year 2026$4.60-$4.64 billion
ROW organic revenue growthfiscal year 2026greater than 5%
Non-GAAP operating marginfiscal year 202623.4%-23.6%
Non-GAAP diluted EPSfiscal year 2026$5.30-$5.40

Key takeaways

  1. NovaSeq X demand remains high after three years

    More than 95 NovaSeq X placements in the quarter show demand holding well beyond launch. Management says this demand continues as it expands workflow and multiomics capabilities.

  2. Clinical customers are the main growth engine

    Clinical markets, about 65% of sequencing consumables revenue, remained the primary growth driver. Management says its technology lets clinical customers expand sequencing-intensive applications.

  3. StrataMap Spatial extends Illumina into spatial biology

    Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, this summer. With over 300 million cells delivered to date, biopharma interest continues to grow.

  4. Multiomics is the second leg of strategy

    Management frames the strategy as the highest quality insights at the lowest end-to-end cost, with multiomics as the next step. The release points to the SomaLogic business and proteomics as part of that push.

  5. Supply investments are rising and costs are shared

    Illumina made significant progress on supply investments in the quarter. Management says those costs are real and that it is sharing some of the increase with customers.

Charts

Revenue$1.2B+9.4% y/yQ2 FY26
Q4 FY24: $1.1B (worked out from the annual figure)Q4 24$1.1BQ1 FY25: $1.0BQ1 25$1.0BQ2 FY25: $1.1BQ2 25$1.1BQ3 FY25: $1.1BQ3 25$1.1BQ4 FY25: $1.2B (worked out from the annual figure)Q4 25$1.2BQ1 FY26: $1.1BQ1 26$1.1BQ2 FY26: $1.2BQ2 26$1.2BQ3 FY26: $1.1BQ3 26$1.1B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$1.1B *
Q1 FY25$1.0B
Q2 FY25$1.1B
Q3 FY25$1.1B
Q4 FY25$1.2B *
Q1 FY26$1.1B
Q2 FY26$1.2B
Q3 FY26$1.1B
Diluted EPS (GAAP)$1.35−9.4% y/yQ2 FY26
Q1 FY25: $0.82Q1 25$0.82Q2 FY25: $1.49Q2 25$1.49Q3 FY25: $0.98Q3 25$0.98Q1 FY26: $0.87Q1 26$0.87Q2 FY26: $1.35Q2 26$1.35Q3 FY26: $1.43Q3 26$1.43
Data
Q1 FY25$0.82
Q2 FY25$1.49
Q3 FY25$0.98
Q1 FY26$0.87
Q2 FY26$1.35
Q3 FY26$1.43

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin21.1%+0.9 pts y/yQ2 FY26
Q4 FY24: 15.9%Q4 2415.9%Q1 FY25: 15.8%Q1 2515.8%Q2 FY25: 20.2%Q2 2520.2%Q3 FY25: 20.9%Q3 2520.9%Q4 FY25: 17.3%Q4 2517.3%Q1 FY26: 19.2%Q1 2619.2%Q2 FY26: 21.1%Q2 2621.1%Q3 FY26: 27.0%Q3 2627.0%
Data
Q4 FY2415.9%
Q1 FY2515.8%
Q2 FY2520.2%
Q3 FY2520.9%
Q4 FY2517.3%
Q1 FY2619.2%
Q2 FY2621.1%
Q3 FY2627.0%
Free cash flow$161.0M−21.1% y/yQ2 FY26
Q4 FY24: $335.0MQ4 24$335.0MQ1 FY25: $208.0MQ1 25$208.0MQ2 FY25: $204.0MQ2 25$204.0MQ3 FY25: $253.0MQ3 25$253.0MQ4 FY25: $266.0MQ4 25$266.0MQ1 FY26: $251.0MQ1 26$251.0MQ2 FY26: $161.0MQ2 26$161.0MQ3 FY26: $379.0MQ3 26$379.0M
Data
Q4 FY24$335.0M
Q1 FY25$208.0M
Q2 FY25$204.0M
Q3 FY25$253.0M
Q4 FY25$266.0M
Q1 FY26$251.0M
Q2 FY26$161.0M
Q3 FY26$379.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

How is NovaSeq X demand holding up?

Demand remained high more than three years after launch, with more than 95 placements in the quarter. The CEO said demand remains high as Illumina expands its workflow and multiomics capabilities.

Who is driving Illumina's growth?

Clinical markets, approximately 65% of sequencing consumables revenue, were the primary growth driver. Illumina says its technology is enabling clinical customers to expand sequencing-intensive applications.

What did Illumina launch this quarter?

Illumina launched StrataMap Spatial this summer, a sequencing-based spatial workflow. Over 300 million cells have been delivered to date and biopharma interest continues to grow.

What is Illumina's strategy beyond sequencing?

Its strategy is to deliver the highest quality insights for the lowest end-to-end cost, with a push into multiomics. The release also names integrating the SomaLogic business as a key factor.

What are the main risks to Illumina's plans?

The release cites SomaLogic integration, proteomics partner and customer relationships, tariffs, and its inclusion on China's Unreliable Entities List. Supply investment costs are also real, and Illumina is sharing some with customers.

Documents

SEC filing